AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for POU domain, class 4, transcription factor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

 Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q01851

UPID:

PO4F1_HUMAN

Alternative names:

Brain-specific homeobox/POU domain protein 3A; Homeobox/POU domain protein RDC-1; Oct-T1

Alternative UPACC:

Q01851; Q14986; Q15318; Q5T227

Background:

POU domain, class 4, transcription factor 1 (POU4F1), also known as Brain-specific homeobox/POU domain protein 3A, plays a pivotal role in neuronal development and function. It acts as a multifunctional transcription factor, regulating genes involved in differentiation, survival, and synaptic protein expression in neuronal lineages. Its ability to activate BCL2 expression and protect neuronal cells from apoptosis highlights its significance in neuroprotection.

Therapeutic significance:

Given its involvement in Ataxia, intention tremor, and hypotonia syndrome, childhood-onset, understanding the role of POU4F1 could open doors to potential therapeutic strategies. Its regulatory effect on gene expression and neuronal survival positions it as a key target for addressing neurodevelopmental disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.